Clinical significance of minimal residual disease detected by multidimensional flow cytometry: Serial monitoring after allogeneic stem cell transplantation for acute leukemia

Leukemia Research

Volumn 36, Issue 8, 2012, Pages 998-1003

  Miyazaki, Takuya ^a   Fujita, Hiroyuki ^a   Fujimaki, Katsumichi ^a   Hosoyama, Takeshi ^b   Watanabe, Reina ^a   Tachibana, Takayoshi ^a   Fujita, Atsuko ^c   Matsumoto, Kenji ^a   Tanaka, Masatsugu ^a   Koharazawa, Hideyuki ^d   Taguchi, Jun ^d   Tomita, Naoto ^a   Sakai, Rika ^c   Fujisawa, Shin ^c   Kanamori, Heiwa ^e   Ishigatsubo, Yoshiaki ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ReproCELL Inc   (Japan)

^c YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^d SHIZUOKA RED CROSS HOSPITAL   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

Author keywords

Acute lymphoblastic leukemia; Acute myeloid leukemia; Allogeneic stem cell transplantation; Minimal residual disease; Multidimensional flow cytometry; Wilms' tumor gene

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ABL1 GENE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; BCR GENE; CBFB GENE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE FUSION; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MLL GENE; MLLT2 GENE; MYELOABLATIVE CONDITIONING; MYH11 GENE; NONMYELOABLATIVE CONDITIONING; ONCOGENE; OVERALL SURVIVAL; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RUNX1 GENE; RUNX1T1 GENE; SURVIVAL TIME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; FEMALE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS; YOUNG ADULT;

EID: 84862522711     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.005     Document Type: Article

References (36)

1. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol 2003, 121:823-838.
2. Chung N.G., Buxhofer-Ausch V., Radich J.P. The detection and significance of minimal residual disease in acute and chronic leukemia. Tissue Antigens 2006, 68:371-385.
3. Grimwade D., Vyas P., Freeman S. Assessment of minimal residual disease in acute myeloid leukemia. Curr Opin Oncol 2010, 22:656-663.
4. Maurillo L., Buccisano F., Del Principe M.I., Del Poeta G., Spagnoli A., Panetta P., et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008, 26:4944-4951.
5. San Miguel J.F., Martinez A., Macedo A., Vidriales M.B., Lopez-Berges C., Gonzalez M., et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997, 90:2465-2470.
6. Coustan-Smith E., Behm F.G., Sanchez J., Boyett J.M., Hancock M.L., Raimondi S.C., et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998, 351:550-554.
7. Loken M.R., Wells D.A. Normal antigen expression in hematopoiesis: basis for interpreting leukemia phenotypes. Immunophenotyping 2000, 133-160. Wiley Liss, New York. C.C. Stewart, J.K.A. Nicholson (Eds.).
8. Walter R.B., Gooley T.A., Wood B.L., Milano F., Fang M., Sorror M.L., et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011, 29:1190-1197.
9. Bacher U., Zander A.R., Haferlach T., Schnittger S., Fehse B., Kroger N. Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008, 42:145-157.
10. Bradfield S.M., Radich J.P., Loken M.R. Graft-versus-leukemia effect in acute lymphoblastic leukemia: the importance of tumor burden and early detection. Leukemia 2004, 18:1156-1158.
11. Diez-Campelo M., Perez-Simon J.A., Perez J., Alcoceba M., Richtmon J., Vidriales B., et al. Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies. Am J Hematol 2009, 84:149-152.
12. Sanchez J., Serrano J., Gomez P., Martinez F., Martin C., Madero L., et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002, 116:686-694.
13. Wells D.A., Sale G.E., Shulman H.M., Myerson D., Bryant E.M., Gooley T., et al. Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation. Am J Clin Pathol 1998, 110:84-94.
14. Miwa H., Beran M., Saunders G.F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992, 6:405-409.
15. Tamaki H., Ogawa H., Ohyashiki K., Ohyashiki J.H., Iwama H., Inoue K., et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 1999, 13:393-399.
16. Trka J., Kalinova M., Hrusak O., Zuna J., Krejci O., Madzo J., et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia 2002, 16:1381-1389.
17. Ostergaard M., Olesen L.H., Hasle H., Kjeldsen E., Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 2004, 125:590-600.
18. Weisser M., Kern W., Rauhut S., Schoch C., Hiddemann W., Haferlach T., et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 2005, 19:1416-1423.
19. Busse A., Gokbuget N., Siehl J.M., Hoelzer D., Schwartz S., Rietz A., et al. Wilms' tumor gene 1 (WT1) expression in subtypes of acute lymphoblastic leukemia (ALL) of adults and impact on clinical outcome. Ann Hematol 2009, 88:1199-1205.
20. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
21. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985, 103:620-625.
22. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
23. Marks R., Potthoff K., Hahn J., Ihorst G., Bertz H., Spyridonidis A., et al. Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies. Blood 2008, 112:415-425.
24. Loken M.R., van de Loosdrecht A., Ogata K., Orfao A., Wells D.A. Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 2008, 32:5-17.
25. Stelzer G.T., Shults K.E., Loken M.R. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann NY Acad Sci 1993, 677:265-280.
26. Sievers E.L., Lange B.J., Alonzo T.A., Gerbing R.B., Bernstein I.D., Smith F.O., et al. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003, 101:3398-3406.
27. Borowitz M.J., Guenther K.L., Shults K.E., Stelzer G.T. Immunophenotyping of acute leukemia by flow cytometric analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. Am J Clin Pathol 1993, 100:534-540.
28. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003, 102:394-403.
29. Krauter J., Wattjes M.P., Nagel S., Heidenreich O., Krug U., Kafert S., et al. Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. Br J Haematol 1999, 107:80-85.
30. Ogawa H., Tamaki H., Ikegame K., Soma T., Kawakami M., Tsuboi A., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003, 101:1698-1704.
31. Neale G.A., Coustan-Smith E., Stow P., Pan Q., Chen X., Pui C.H., et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004, 18:934-938.
32. Kerst G., Kreyenberg H., Roth C., Well C., Dietz K., Coustan-Smith E., et al. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005, 128:774-782.
33. Bene M.C., Kaeda J.S. How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. Haematologica 2009, 94:1135-1150.
34. Radich J., Gehly G., Lee A., Avery R., Bryant E., Edmands S., et al. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. Blood 1997, 89:2602-2609.
35. Elmaagacli A.H., Beelen D.W., Kroll M., Trzensky S., Stein C., Schaefer U.W. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation. Bone Marrow Transplant 1998, 21:159-166.
36. van der Velden V.H., Hochhaus A., Cazzaniga G., Szczepanski T., Gabert J., van Dongen J.J. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034.